




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C07D 405/14, A61K 31/41, C07F 9/6558,</b> <b>A61K 31/66</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 99/15522</b> <b>(43) International Publication Date:</b> 1 April 1999 (01.04.99)
<b>(21) International Application Number:</b> PCT/US98/18508 <b>(22) International Filing Date:</b> 22 September 1998 (22.09.98) <b>(30) Priority Data:</b> 08/937,827      25 September 1997 (25.09.97)      US <b>(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application</b> US      08/937,827 (CIP) Filed on      25 September 1997 (25.09.97) <b>(71) Applicant (for all designated States except US):</b> SCHERING CORPORATION [US/US]; 2000 Galloping Hill Road, Kenilworth, NJ 07033 (US). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> BENNETT, Frank [GB/US]; 419 Draco Road, Piscataway, NJ 08854 (US). GIRIJAVALLABHAN, Viyyoor, M. [US/US]; 10 Maplewood Drive, Parsippany, NJ 07054 (US). PATEL, Naginbhai, M. [US/US]; 19 Jersey Avenue, Piscataway, NJ 08854 (US). SAKSENA, Anil, K. [US/US]; 53 Beverly Road, Upper Montclair, NJ 07043 (US). GANGULY, Ashit		[US/US]; 96 Cooper Avenue, Upper Montclair, NJ 07043 (US). <b>(74) Agents:</b> HOFFMAN, Thomas, D. et al.; Schering-Plough Corporation, Patent Dept., K-6-1 1990, 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US). <b>(81) Designated States:</b> AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CZ, EE, GD, GE, HR, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>

 Reference AK for  
 Serial No. 10/786,886

**(54) Title:** TETRAHYDROFURAN PHOSPHATE- AND HYDROXY ESTERS, AS PRODRUGS FOR THE CORRESPONDING ANTIFUNGAL AGENT



(I)

**(57) Abstract**

A compound of formula (I) wherein G is H or PO<sub>3</sub>H<sub>2</sub> or a pharmaceutical acceptable salt thereof, pharmaceutical compositions containing such compounds and method of using such compounds or pharmaceutical compositions containing them to treat or prevent fungal infection are disclosed.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

TETRAHYDROFURAN PHOSPHATE- AND HYDROXY ESTERS, AS PRODRUGS FOR THE  
CORRESPONDING ANTIFUNGAL AGENT

**Background of the Invention**

This invention relates to a tetrahydrofuran antifungal phosphate which is named: 5-[[[2(S)-[4-[4-[4-[4-[(R-cis)-5-(2,4-difluorophenyl)-tetrahydro-5-(1H-1,2,4-triazol-1-ylmethyl)-3-furanyl] methoxy]phenyl]-1-piperazinyl]phenyl]-4,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]-1(S)-methylbutyl]oxy]-5-oxobutyl phosphate, and to a tetrahydrofuran antifungal butyrate which is named: (-)-2(S)-[4-[4-[4-[4-[(R-cis)-2-(2,4-difluorophenyl) tetrahydro-2- (1H-1,2,4-triazol-1-ylmethyl)-4-furanyl]methoxy]phenyl]-1-piperazinyl]phenyl]-4, 5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]-1(S)-methylbutyl 4-hydroxybutanoate and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing such antifungals and methods of treating or preventing fungal infections in hosts using them.


International Publication Nos. WO 96/38443 (published 5 Dec 1996) and WO 95/17407 (published 29 June 1995) disclose various tetrahydrofuran antifungals and phosphate esters thereof but neither one discloses the tetrahydrofuran antifungal compounds of the present invention.

There is a need for a broad spectrum antifungal agent having solubility suitable for parenteral administration and a favorable activity profile for treating and/or preventing systemic fungal infections, especially Aspergillus, Candida, Cryptococcus and opportunistic infections.

**Summary of the Invention**


The present invention also provides a compound represented by the formula I

2




wherein G is H or  $\text{PO}_3\text{H}_2$  or a pharmaceutically acceptable salt thereof.

The present invention provides a compound represented by the formula II



or a pharmaceutically acceptable salt thereof.


The present invention provides a compound represented by formula III



or a pharmaceutically acceptable salt thereof.


### **Detailed Description of the Invention and of the Preferred Embodiments**

The compound of the present invention of formula II in the form of a pharmaceutically acceptable salt such as the di N-methylglucamine ("NMG") salt represented by formula II.2NMG is a water soluble prodrug which is converted *in vivo* into the active metabolite III which is also converted *in vivo* into the antifungal agent represented by formula IV according to the following equations:



The compound of formula II hydrolyzes *in vivo* to the compound of formula III ; III then hydrolyzes *in vivo* to the compound of formula IV. The hydrolysis of II to III occurs primarily in the serum and in tissues (liver, lung and kidney). The hydrolysis of III to IV occurs primarily in the serum.

The compound of formula II upon intravenous administration to mice in the form of its di-NMG salt represented by formula II.2NMG in water provides superior blood levels of the compound of formula IV in mice. See Tables 1 -3.



When an aqueous solution of the di-NMG salt of the compound of formula II ( II.2NMG )was administered intravenously to mice in a side-by-side comparison with the di-NMG salt of the compound of formula V (disclosed in WO 95/17407 at the lower right hand corner of page 15), the pharmacokinetic parameters of the compound of formula IV derived from the di-NMG salt of the compound of formula the II of this invention were unexpectedly superior to those of the compound of formula IV derived from the di-NMG salt of the prior art compound of formula V. The results are summarized in Table 3




Table 1

Concentrations of the compound of formula IV in pooled mouse<sup>1</sup> plasma (2 mice/pool) following intravenous administration of a 20 mg/kg of the compound of formula IV dose equivalent of the di-NMG salt of the compound of this invention represented by the formula II in sterile water.

hr	$\mu\text{g/ml}$		Mean	%CV <sup>3</sup>
	Pool 1	Pool 2		
0 (undosed)	0.000 <sup>2</sup>	0.000	0.000	
0.017 (1 min)	0.171	0.164	0.168	2.95
0.05 (3 min)	0.378	0.297	0.338	16.9
0.083 (5 min)	0.798	0.817	0.808	1.66
0.25 (15 min)	1.57	2.72	2.15	37.9
0.5 (30 min)	3.02	2.34	2.68	17.9
1 hr.	4.46	3.95	4.21	8.58
3 hr.	5.16	5.63	5.40	6.16
6 hr.	5.96	3.59	4.78	35.1
24 hr.	0.915	0.992	0.954	5.71
Cmax ( $\mu\text{g/ml}$ )			5.40	
Tmax (hr)			3	
AUC(0-24hr) ( $\mu\text{g}\cdot\text{hr/ml}$ )			79.1	

<sup>1</sup> Male Charles River mice having an average body weight of 18-20 g obtained from Charles River, Wilmington, MA 01887

<sup>2</sup> Values below the lower limit of quantitation of 0.05  $\mu\text{g/ml}$  are reported as zero.

<sup>3</sup> %CV is percent coefficient of variation which is a relative measure of variability. See Steele and Torrie, "Principles and Procedures of Statistics", (1980) 2nd Edition, McGraw-Hill, NY, at page 27.

Table 2

Concentrations of the compound of formula IV in pooled mouse<sup>1</sup> plasma (2 mice/pool) following intravenous administration of a 20 mg/kg of compound of formula IV dose equivalent of the di-NMG salt of the compound of the prior art represented by formula V in sterile water.

hr	<u>µg/ml</u>		Mean	%CV <sup>4</sup>
	Pool 1	Pool 2		
0 (undosed)	0.000 <sup>1</sup>	0.000	0.000	—
0.017 (1 min)	0.000	0.000	0.000	—
0.05 (3 min)	0.738	0.663	0.723	11.7
0.083 (5 min)	1.04	1.43	1.24	22.3
0.25 (15 min)	1.22	0.407	0.814	70.6
0.5 (30 min)	1.99	— <sup>3</sup>	1.99	—
1 hr.	2.73	2.63	2.68	2.64
3 hr.	0.923	2.51	1.72	65.4
6 hr.	2.59	1.90	2.25	21.7
24 hr.	0.447	0.515	0.481	10.0
Cmax (µg/ml)			2.68	
Tmax (hr)			1	
AUC(0-24hr) (µg.hr/ml)			36.7	

<sup>1</sup> Male Charles River mice having an average body weight of 18-20g obtained from Charles River, Wilmington, MA 01887

<sup>2</sup> Values below the lower limit of quantitation of 0.05 µg/ml are reported as zero.

<sup>3</sup> Connection between detector and computer was lost; therefore this value was lost.

<sup>4</sup>%CV is percent coefficient of variation which is a relative measure of variability. See Steele and Torrie, "Principles and Procedures of Statistics", (1980) 2nd Edition, McGraw-Hill, NY, at page 27.



Table 3

PHARMACOKINETIC ("PK") PARAMETERS OF THE COMPOUND OF FORMULA IV IN MOUSE<sup>1</sup> PLASMA FOLLOWING INTRAVENOUS ADMINISTRATION OF 20 MG/KG OF COMPOUND OF FORMULA IV DOSE EQUIVALENT OF THE DI-NMG SALTS OF THE COMPOUNDS OF FORMULAS II AND V IN STERILE WATER TO MICE.

PK Parameters of the Compound of Formula IV

Compound Administered	C <sub>max</sub> (µg/mL)	T <sub>max</sub> (hr)	AUC <sup>2</sup> (µg.hr/min)	Bioavailability (%)
Formula II.2NMG	5.40	3	79.1	65
Formula V.2NMG	2.68	1	36.7	30

<sup>1</sup> Male Charles River mice having an average body weight of 18-20g obtained from Charles River, Wilmington, MA 01887.

<sup>2</sup> Area under the curve measured from time zero to 24 hrs. in (µg.hr/min).

Table 3 summarizes and compares the pharmacokinetic parameters listed in Tables 1 and 2. The pharmacokinetic parameters for the compound of formula IV derived from the di -NMG salt of the compound of the present invention (II.2NMG) are superior to the pharmacokinetic values for the compound of formula IV derived from the di-NMG salt of the prior art compound of formula V.

The pharmacokinetic parameters of the compound of formula IV obtained upon analysis of mouse plasma from mice intravenously injected with the compound of the present invention represented by formula II of this invention were surprisingly unexpectedly superior to those obtained from mouse plasma from mice intravenously injected with the compound of the prior art represented by formula V (see Tables 1-3).

The term "opportunistic fungi" include Cryptococcus, Histoplasma, Blastomyces, Coccidioides, Fusarium, Mucor, Paracoccidioides, Fonsecaea, Wangiella, Sporothrix, Pneumocystis, Trichosporon as shown by in vitro and/or in vivo activity in an appropriate animal species e.g. mouse, rat or rabbit. The compounds of the invention is expected to exhibit activity against many genera and species of protoza, bacteria, gram negatives, gram positives, anaerobes, including Legionella Borrelia, Mycoplasma, Treponema, Gardnerella, Trichomonas and Trypanosoma.

The compounds of this invention represented by formulas I - III are expected to exhibit broad spectrum antifungal activity against human and animal pathogens, such as the following: *Aspergillus*, *Blastomyces*, *Candida*, *Cryptococcus*, *Coccidioides*, *Epidermophyton*, *Fonsecaea*, *Fusarium*, *Mucor*, *Saccharomyces*, *Torulopsis*, *Trichophyton* , *Trichosporon*, *Sporothrix* and *Pneumocystis*.

The compounds of formulas III and IV- the in vivo conversion products of the compound of formula II-exhibit antifungal activity in in vivo tests in mice and such activity is unexpectedly better than that of existing antifungal agents e.g. itraconazole and fluconazole as well as that of the azole compounds specifically disclosed by Saksena et al. in USP 5,039,676 and International Publication No. WO 93/09114.

The in vitro anti-fungal activities of the compounds of the formulas II, III and IV against forty-one species of *Candida*, thirty species of *Aspergillus* and nine species of *Cryptococcus* are summarized in Table 5. Based on a comparison of the geometric mean MICs (mcg/mL), the in vitro antifungal activities of the compounds of the formulas III and IV are similar to one another; the in vitro activity of II is much lower. The compound of formula II showed good in vivo activity in two mice models. Doses of 10 mg/kg of II provided 100% survival at day 9 in mice with a systemic *Candida albicans* infection and 70% survival in mice with a pulmonary *Aspergillus fumigatus* infection; fluconazole is inactive in this *Aspergillus* pulmonary infection

model in mice. This *Aspergillus* pulmonary infection model in mice was performed in accordance with the procedures of David Loebenberg et al. entitled "In vitro and in vivo activity of Sch 42427, the active enantiomer of the antifungal agent Sch 39304" published in Antimicrobial Agents and Chemotherapy (1992), Vol. 36, pp. 498-501.

Pharmacokinetic studies in human tissues and serum indicated that the compound of formula II is metabolized to the compound of formula IV via the metabolite represented by formula III. Plasma levels in cynomolgus monkeys following intravenous (IV) infusion of the compound of formula II as the di NMG salt show the following pharmacokinetic (PK) profile summarized in Table 4.

Table 4  
Cynomolgus Monkey PK Levels Following Intravenous Infusion of II.2NMG

<u>Compound</u>	<u>C<sub>max</sub>(µg/mL)</u>	<u>AUC<sup>1</sup></u>
II	40.7	3.98
III	4.8	4.41
IV	1.04	24.11

1. The area under the curve measured from time zero to 48 hours, i.e., AUC (0-48 hrs) in µg.hr/mL.

The antifungal compounds of formulas I - III and pharmaceutical compositions of these compounds are expected to exhibit anti-allergic, anti-inflammatory and immunomodulating activities, broad spectrum anti-infective activity, e.g., antibacterial, anti-protozoal and antihelminthic activities in mammals, especially man.

The present invention also provides a composition for treating or preventing fungal infections comprising an antifungally effective amount of the compound represented by formula I or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent therefor.

The pharmaceutical compositions of the present invention may also contain a fungicidally effective amount of other antifungal compounds such as cell wall active compounds. The term "cell wall active compound", as used herein, means any compound that interferes with the fungal cell wall and includes, but is not limited to, compounds such as papulacandins, echinocandins, and aculeacins as well as fungal cell wall inhibitors such as nikkomycins, and others which are described in USP 5,006,513 which is hereby incorporated by reference.

Table 5

## In Vitro Antifungal Activity(mcg/mL)

<u>Compound</u>	<u>Microorganisms</u>	<u>G mean MICs<sup>1</sup></u>	<u>Range</u>
II	<i>Aspergillus</i> <sup>2</sup> species (n=30)	5.9	0.5 to >32
II	<i>Candida</i> <sup>3</sup> species (n=41) <sup>2</sup>	7.5	1 to >32
II	<i>Cryptococcus</i> <sup>3</sup> <i>neoformans</i> (n=9) <sup>3</sup>	1.9	0.125 to 32
III	<i>Aspergillus</i> <sup>2</sup> species (n=30)	0.2	0.0313 to 2
III	<i>Candida</i> <sup>3</sup> species (n=41)	0.3	≤ 0.0156 to 8
III	<i>Cryptococcus</i> <sup>3</sup> <i>neoformans</i> (n=9)	0.09	0.0156 to 0.5
IV	<i>Aspergillus</i> <sup>2</sup> species (n=30)	0.1	≤0.0156 to 1
IV	<i>Candida</i> <sup>3</sup> species (n=41)	0.2	≤0.0156 to 8
IV	<i>Cryptococcus</i> <sup>3</sup> <i>neoformans</i> (n=9)	0.04	≤0.0150 to 0.5

<sup>1</sup> Geometric means MICs<sup>2</sup> In vitro activity against *Aspergillus* measured in accordance with Espinel-Ingroff's Methodology<sup>3</sup> In vitro activity measured in accordance with procedures for NCCLS standard M27A.

The pharmaceutically acceptable salts of the compounds of the present invention include pharmaceutically acceptable basic addition salts.

The pharmaceutically acceptable bases found suitable for use in the present invention are those which form pharmaceutically acceptable salts of the acidic antifungal compounds of formulas I or II and include suitable organic and inorganic bases. Suitable organic bases include primary, secondary and tertiary alkyl amines, alkanolamines, aromatic amines, alkylaromatic amines and cyclic amines. Exemplary organic amines include the pharmaceutically acceptable bases selected from chlorprocaine, procaine, piperazine, glucamine, N-methylglucamine, N,N-dimethylglucamine, ethylenediamine, diethanolamine, diisopropylamine, diethylamine, N-benzylendiamine, diethanolamine, diisopropylamine, diethylamine, N-benzyl-2-phenylethylamine, N,N'-dibenzylethylenediamine, choline, clemizole, triethylamine ("Et<sub>3</sub>N"), tris(hydroxymethyl)aminomethane, or D-glucosamine. The preferred organic bases include N-methylglucamine ("NMG"), diethanolamine, and tris(hydroxymethyl)aminomethane ("TRIS"). Use of two equivalents of NMG in this invention is more preferred. The suitable inorganic bases also include alkali metal hydroxides such as sodium hydroxide.

The pharmaceutical compositions of the present invention may be adapted for any mode of administration e.g., for oral, parenteral, e.g., SC, IM, IV and IP, topical or vaginal administration or by inhalation (orally or intranasally) Such compositions are formulated by combining the compound of formula II or one or two equivalents of a pharmaceutically base, e.g. NMG to form a acceptable salt of the formula II.2NMG with a suitable, inert, pharmaceutically acceptable carrier or diluent.

Examples of suitable compositions include solid or liquid compositions for oral administration such as tablets, capsules, pills, powders, granules, solutions, suppositories, troches, lozenges, suspensions or emulsions. A solid carrier can be one or more substances which may also act as diluents, flavoring agents,

solubilizers, lubricants, suspending agents, binders or tablet disintegrating agents; it can also be an encapsulating material. In powders, the carrier is a finely divided solid which is in admixture with the finely divided active compound. In the tablet, the active compound is mixed with carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.

Topical dosage forms may be prepared according to procedures well known in the art, and may contain a variety of ingredients, excipients and additives. The formulations for topical use include ointments, creams, lotions, powders, aerosols, pessaries and sprays.

For preparing suppositories, a low melting wax such as a mixture of fatty acid glycerides or cocoa butter is first melted, and the active ingredients are dispersed homogeneously therein as by stirring. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool and thereby solidify.

Liquid form preparations include solutions, suspensions and emulsions. As an example may be mentioned water or water-propylene glycol solutions for parenteral injection. Liquid preparations can also be formulated in solution with an appropriate amount of a hydroxypropyl  $\alpha$ -  $\beta$  or  $\gamma$ -cyclodextrin having 2 to 11 hydroxypropyl groups per molecule of cyclodextrin, polyethylene glycol, e.g., PEG-200 or propylene glycol, which solutions may also contain water. Aqueous solutions suitable for oral use can be prepared by adding the active component in water and adding suitable colorants, flavors, stabilizing, sweetening, solubilizing and thickening agents as desired. Aqueous suspensions suitable for oral use can be made by dispersing the active component in finely divided form in water. A particularly preferred aqueous pharmaceutical composition may be prepared from the compound of formula I together with hydroxypropyl- $\beta$ -cyclodextrin in water. The use of derivatives of  $\alpha$ -,  $\beta$ - and  $\gamma$ -cyclodextrins, for example, hydroxypropyl- $\beta$ -cyclodextrin are disclosed by N. Bodor USP 4,983,586, Pitha USP 4,727,064 and Janssen Pharmaceutical International Patent Application No. PCT/EP 84/00417.

The pharmaceutical compositions of the present invention may be prepared by admixing the pharmaceutically acceptable carrier, e.g., a hydroxypropyl- $\beta$ -cyclodextrin in water, and adding thereto an

antifungally effective amount of the compound of the present invention. The solution so formed is filtered, and optionally, the water may be removed by well known methods, e.g., rotatory evaporation or lyophilization. The formation of the solution may take place at a temperature of about 15° to 35°C. The water is normally sterilized water and may also contain pharmaceutically acceptable salts and buffers, e.g., phosphate or citrate as well as preservatives. The molar ratio of the antifungal compound of formula I to hydroxypropyl- $\beta$ -cyclodextrin is about 1:1 to 1:80, preferably 1:1 to 1:2. Normally the hydroxypropyl- $\beta$ - is present in molar excess.

Also included are solid form preparations which are intended to be converted, shortly before use, into liquid form preparations for either oral or parenteral administration. The solid form preparations intended to be converted to liquid form may contain, in addition, to the active materials, such as compounds of this invention, and optionally a cell wall active compound, especially a fungal cell wall inhibitor, e.g., a nikkomycin, flavorants, colorants, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents and the like. The solvent utilized for preparing the liquid form preparations may be water, isotonic water, ethanol, glycerin, polyethylene glycols, propylene glycol, and the like, as well as mixtures thereof.

Parenteral forms to be injected intravenously, intramuscularly, or subcutaneously are usually in the form of a sterile solution, and may contain salts or glucose to make the solution isotonic.

The topical dosage for humans for antifungal use in the form of a pharmaceutical formulation comprising a compound of formula I (usually in the concentration in the range from about 0.1% to about 20% preferably from about 0.5% to about 10% by weight) together with a non-toxic, pharmaceutically acceptable topical carrier, is applied one or more times daily to the affected skin until the condition has improved.

In general, the oral dosage for humans for antifungal use ranges from about 1 mg per kilogram of body weight to about 30 mg per kilogram of body weight per day, in single or divided doses, with about 1 mg per kilogram of body weight to about 20 mg per kilogram of body weight per day being preferred and the dose of about 1 mg per



15

kilogram of body weight to about 10 mg per kilogram of body weight per day being most preferred.

In general, the parenteral dosage for humans for antifungal use ranges from about 1 mg per kilogram of body weight per day to about 30 mg per kilogram of body weight per day, in single or divided doses, with about 1 to about 20 mg per kilogram of body weight per day being preferred and the dose of about 1 mg per kilogram of body weight to about 8 mg per kilogram of body weight per day in single or divided doses being most preferred.

Intravenous (IV) infusion is the preferred mode of administration. Single or divided doses of 200-450 mg twice a day by IV infusion are preferred. Doses of 200-250 mg twice a day by IV infusion are most preferred


The exact amount, frequency and period of administration of the compounds of the present invention for antifungal use will vary, of course, depending upon the sex, age and medical condition of the patient as well as the severity of the infection as determined by the attending clinician.

### Experimental

#### Example 1


A preparation of the compound of formula II and the salt of formula II.2NMG

Step (A)



To a stirred mixture of 10 g (14 mmol) of the compound of formula IV (prepared in accordance with the procedure of Example 32 of WO 96/38443, published 5 December 1996) and 2.27 g, (1.3 eq) of the base, 4-(N,N-dimethylamino)pyridine ("DMAP") in 200 mL of methylene chloride, 4-bromobutyl chloride (1.3 eq, 18.6 mmol, 3.44g) was added dropwise and the resulting reaction mixture was stirred at room temperature until the reaction was determined to be complete by thin layer chromatography ("TLC"). The reaction mixture was partitioned between saturated aqueous sodium bicarbonate and ethyl acetate ("EtOAc"). The organic phase was separated, washed with water and dried over  $\text{MgSO}_4$ . The organic solvent was removed and the so-formed residue was purified on a silica gel chromatography column using EtOAc as the eluent to provide 8.58 g of the bromide VI as a white solid.

Step (B)




To a stirred solution of the bromide VI of Step A (3.44 g, 4.0 mmol) in 200 ml of dry benzene was added, silver dibenzylphosphate (available from Sigma Chemical Co., St. Louis) (2.0 eq, 8.2 mmol, 3.14g) and the resulting reaction mixture was heated to reflux for a period of 20 hours. The reaction mixture was cooled and filtered and the filtrate was partitioned between EtOAc and 10% aqueous HCl. The organic phase was separated, washed with water, dried over  $\text{MgSO}_4$  and concentrated under reduced pressure to provide a residue. The residue was purified on silica gel chromatographic column using

17

EtOAc: MeOH (20:1 (v/v)) as eluent to provide 0.976g of the starting material bromide VI and 1.221g of the desired dibenzylphosphate VII as a light brown solid.

### Step (C)




A stirred suspension of 10% Pd on carbon (0.60g) and the dibenzylphosphate VII (1.2g 1.14 m mol) of step B in EtOH (40 mL) and acetic acid("HOAc") (40 mL) was placed under an atmosphere of hydrogen gas at room temperature overnight (or 16 hours). The reaction mixture was then filtered through a pad of celite and the solid pad was washed thoroughly with methanol. The combined filtrates were concentrated under reduced pressure to yield 0.976g of the compound II as a light brown solid.  $^1\text{H}$  nmr :  $\delta$  H ( $\text{CD}_3\text{OD}$ ), 8.38 (s,1), 8.06 (s, 1), 7.77 (s,1), 7.42-7.48(m, 2), 7.34-7.42 (m,1) 7.06-7.23 (m,5), 6.96-7.03 (m,1), 6.83-6.90 (m, 2), 5.13-5.22 (m, 1) 4.67 (s,2), 4.09-4.17 (m, 2), 3.70-3.91 (m, 4), 3.39-3.45 (m, 4), 3.24-3.30 (m, 4), 2.50-2.65 (m, 2), 2.30-2.38 (m, 2), 2.14-2.22 (m, 1), 1.74-1.98 (m,4), 1.30 (d, 3) and 0.88 (t, 3).

FABMS (Found:  $[\text{MH}^+]$  867.3404; Calcd : $[\text{MH}^+]$  867.3406.

18

Step (D)




To the product II of step C, (0.940 g, 1.08 mmol) was added N-methylglucamine (2 eq, 2.17 mmol, 0.423 g) in 10 mL of water. The resulting solution was filtered and the filtrate was concentrated under a stream of nitrogen to provide 1.396 g of the di NMG salt represented by the formula II.2NMG as a light brown solid.

$^1\text{H}$  nmr:  $\delta_{\text{H}}$  ( $\text{CD}_3\text{OD}$ ), 8.37 (s, 1), 8.08 (s, 1), 7.76 (s, 1), 7.42-7.46 (m, 2), 7.34-7.41 (m, 1), 7.11-7.16 (m, 2), 6.96-7.02 (m, 3), 6.80-6.90 (m, 3), 5.14-5.22 (m, 1), 4.66 (s, 2), 4.10-4.16 (m, 2), 3.96-4.03 (m, 2), 3.60-3.87 (m, 14), 3.35-3.40 (m, 4), 3.18-3.23 (m, 4), 2.88-3.01 (m, 4), 2.50-2.65 (m, 2), 2.56 (s, 6), 2.34-2.41 (m, 2), 2.15-2.22 (m, 1), 1.76-1.96 (m, 4), 1.30 (d, 3) and 0.87 (t, 3).

### Example 2


Preparation of the Compound of Formula III: 2(S)-[4-{4-{4-{4-[(R-Cis)-2-(2,4-difluorophenyl)-tetrahydro-2-(1H-1,2,4-triazol-1-ylmethyl)-4-furanyl]methoxy]phenyl]-1-piperazinyl]phenyl]-4,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]-1-(S)-methylbutyl-4-hydroxy-butanoate

## Step (A)



To a stirred suspension of 0.29 g of a 60% dispersion of sodium hydride in mineral oil (1 eq, 0.19 g, of sodium hydride) in 5 mL of dimethyl formamide ("DMF") at room temperature under an atmosphere of nitrogen was added 1.00 g (7.7 mmol) of 4-hydroxybutyric acid, sodium salt. The so-formed reaction mixture was stirred for 30 minutes and 1.36 g (1 eq, 0.94 mL) of benzyl bromide was added. The resulting reaction mixture was stirred overnight. After an aqueous workup, the crude product was isolated and purified on a silica gel chromatography column using ETOAc-hexane (1:20, v/v) as an eluent to produce 0.271 g of the benzyl ester, benzyl 4-benzyloxybutyrate.


## Step (B)



Sodium hydroxide (2, eq, 1.9 mmol, 73 mg) was added in one portion to a stirred mixture of 0.27 g (0.95 mmol) of the benzyl ester from Step (A) in a solution of 3 mL of methanol and 1 mL of water. The so-formed mixture was stirred for 3 hrs. and then concentrated under reduced pressure. The so-formed residue was partitioned between diethyl ether (Et<sub>2</sub>O) and water. The aqueous phase was separated, washed with Et<sub>2</sub>O, acidified with aqueous HCl and CH<sub>2</sub>Cl<sub>2</sub> was added. The organic phase was dried over MgSO<sub>4</sub> and concentrated to give 0.153 g of 4-benzyloxybutyric acid as a colorless oil.

20

Step (C)




To a stirred mixture of 1.0g of 4-benzyloxybutyric acid from Step (B) 0.507 mmol, 3.62 g of the compound of formula IV (prepared in accordance with the procedure of Example 32 of WO 96/38443, published 5 December 1996) and 0.82 g of the base, 4-(N,N-dimethylamino)pyridine ("DMAP") in 50 mL of methylene chloride, 1.26g of dicyclohexylcarbodiimide ("DCC") were added and the resulting reaction mixture was stirred at room temperature until the reaction was determined to be complete (4 hrs) by thin layer chromatography ("TLC"). The reaction mixture was partitioned between 5% aqueous citric acid and EtOAc. The organic phase was separated, washed with water and dried over MgSO<sub>4</sub>. The organic solvent was removed and the so-formed residue was purified on a silica gel chromatography column using EtOAc as the eluent to provide 2.8 g of the benzyl ether VIII. The <sup>1</sup>H NMR was consistent with the structure of VIII.

FABMS (Found :[MH]<sup>+</sup>, 877.4182 C<sub>48</sub>H<sub>55</sub>N<sub>8</sub>O<sub>8</sub>F<sub>2</sub> requires 877.4213);  
 [α]<sub>D</sub><sup>24</sup> = (-) 56.5° (c, 1.01; CHCl<sub>3</sub>); <sup>1</sup>H nmr : δH (CDCl<sub>3</sub>), 8.12 (s,1), 7.80 (s,1), 7.58 (d,1), 7.24-7.43 (m, 8), 6.75 -7.01 (m, 8), 5.18 -5.27 (m,1), 4.64 (A of AB, 1), 4.52 (B of AB, 1), 4.44 (s, 2), 4.16-4.24 (m,1), 4.09 -4.14 (m, 1), 3.76 -3.81 (m, 1), 3.68-3.74 (m, 1), 3.59 -3.65 (m, 1), 3.41-3.46 (m, 2), 3.30 -3.36 (m, 4), 3.18-3.24 (m,4), 2.51-2.66 (m,2), 2.34-2.40 (m, 2), 2.05 -2.12 (m, 1), 1.74-1.99 (m, 4), 1.29 (d, 3), and 0.89 (t, 3).

21


Step(D)



To a stirred solution of 1.0 g of benzyl ether **VIII** (prepared in accordance with Step (C) of Example 2) and 1 mL of formic acid in 40 mL of methanol was added 0.5 g of palladium black catalyst. The so-formed reaction mixture was heated to reflux for 15 min. The reaction mixture was cooled to room temperature and the Pd catalyst was removed by filtration. The filtered catalyst was washed with methanol. The combined methanol fractions were concentrated and purified on a silica gel chromatography column using 5% methanol in EtOAc as an eluent to provide 0.7 g of the alcohol of formula **III**.


FABMS (Found:[MH]<sup>+</sup> 787.3743. C<sub>41</sub>H<sub>49</sub>N<sub>8</sub>O<sub>6</sub>F<sub>2</sub> requires 787.3714); [α]<sub>D</sub><sup>24</sup>=(-) 64.80 (c,1.03; CHCl<sub>3</sub>); <sup>1</sup>H nmr: δH(CDCl<sub>3</sub>), 8.11 (s,1), 7.80 (s,1), 7.64(s,1), 7.35-7.45 (m,3), 6.99-7.05 (m,2), 6.89-6.95 (m,2), 6.75-6.89 (m,4), 5.19-5.27 (m,1), 4.65 (A of AB,1), 4.51 (B of AB,1), 4.18-4.24 (m,1), 4.08-4.15 (m,1), 3.75-3.81(m,1), 3.68-3.73 (m,1), 3.53-3.65 (m,3), 3.32-3.40 (m,4), 3.18-3.26 (m,4), 2.51-2.66 (m,2), 2.34-2.41(m,2), 2.04-2.12 (m,1), 1.88-1.99 (m,1), 1.74-1.84 (m,3), 1.32 (d,3) and 0.90 (t,3).

## Step (E)



To a stirred solution of the alcohol **III** (0.140 g, 0.18 mmol.) of Step(D) of Example 2 and tetrazole (0.53 mmol, 3 eq, .037 g) in 5 mL of  $\text{CH}_2\text{Cl}_2$ , N,N-diisopropylidibenzylphosphoramidite (1.5 eq, 0.27 mmol, 0.0922 g) was added dropwise and the so-formed reaction mixture was stirred at room temperature for a period of 1 hr. A solution of tert-butylhydroperoxide (3 eq, 90  $\mu\text{L}$  of a 5.5 molar solution in iso-octanol) was then added to the stirred reaction mixture the stirring was maintained for 3 additional hours. The so-formed reaction mixture was partitioned between a 10% aqueous sodium thiosulfate solution and ethanol. The organic phase was separated, washed with saturated sodium bicarbonate and dried over anhydrous sodium sulfate. The organic phase was concentrated and purified on a silica gel chromatography column using EtOAc-methanol (20:1,v/v) as an eluent to give 0.1389 g of the dibenzylphosphate compound having a structure by  $^1\text{H}$  nmr consistent with that of formula **VII** of Step B of Example 1.

## Step (F)






The compound VII of Step(C) of Example 2 was treated in accordance with the procedure of Step(C) of Example 1 to give the title compound of formula II.

What is claimed is

1. A compound represented by the formula I:




wherein G is H or  $-PO_3H_2$   
or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising an antifungally effective amount of the compound of claim 1 and a pharmaceutically acceptable carrier.
3. The pharmaceutical composition of claim 2 adapted for parenteral administration.
4. The pharmaceutical composition of claim 2 adapted for intravenous administration.
5. The pharmaceutical composition of claim 2 adapted for intravenous infusion administration.
6. A method of treating or preventing a fungal infection in a host which comprises administering to said host an antifungally effective amount of the compound of claim 1.

25

7. A method of treating or preventing a fungal infection in a host which comprises parenterally administering to said host an antifungally effective amount of the compound of claim 1.

8. A compound represented by the formula II:



or a pharmaceutically acceptable salt thereof.

9. A pharmaceutical composition comprising an antifungally effective amount of the compound of claim 8 and a pharmaceutically acceptable carrier.

10. The pharmaceutical composition of claim 9 adapted for parenteral administration.


11. The pharmaceutical composition of claim 9 adapted for intravenous administration.

12. The pharmaceutical composition of claim 9 adapted for intravenous infusion administration.


13. A method of treating or preventing a fungal infection in a host which comprises administering to said host an antifungally effective amount of the compound of claim 9.

14. A method of treating or preventing a fungal infection in a host which comprises parenterally administering to said host an antifungally effective amount of the compound of claim 9 or a pharmaceutically acceptable salt thereof.

15. The compound of claim 8 in the form of the di-N-methylglucamine salt which is named 5-[(2(S)-[4-[4-[4-[(r-cis)-5-(2,4-difluorophenyl)-tetrahydro-5-(1H-1,2,4-triazol-1-ylmethyl)-3-furanyl]methoxy]phenyl]-1-piperazinyl]phenyl]-4,5-dihydro-5-oxo-1h-1,2,4-triazol-1-yl]-1(S)-methylbutyl]oxy]-5-oxobutyl phosphate, di-N-methylglucamine salt and represented by the formula II.2NMG



16. A compound represented by the formula III:



or a pharmaceutically acceptable salt thereof.

17. A pharmaceutical composition comprising an antifungally effective amount of the compound of claim 16 and a pharmaceutically acceptable carrier.

18. The pharmaceutical composition of claim 17 adapted for parenteral administration.

19. A method of treating or preventing a fungal infection in a host which comprises administering to said host an antifungally effective amount of the compound of claim 16.

20. A method of treating or preventing a fungal infection in a host which comprises parenterally administering to said host an antifungally effective amount of the compound of claim 16.

# INTERNATIONAL SEARCH REPORT

Ir. ational Application No

PCT/US 98/18508

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D405/14 A61K31/41 C07F9/6558 A61K31/66

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 95 17407 A (SCHERING CORPORATION) 29 June 1995 cited in the application see page 6, line 11 - page 7, line 2 see compounds IV, pages 14-17 see page 17 see scheme VIIIB, page 30 see page 31 see claims 7,9-13 ---	1-5, 8-12, 15-18
P,X	US 5 693 626 A (SAKSENA A.K. ET AL.) 2 December 1997 see third compound see claim 5 -----	1,8

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

16 December 1998

Date of mailing of the international search report

29.12.98

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Hartrampf, G

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 98/18508

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 6, 7, 13, 14, 19, 20  
because they relate to subject matter not required to be searched by this Authority, namely:  
Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

In International Application No

PCT/US 98/18508

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9517407 A	29-06-1995	AU 681753 B	04-09-1997
		AU 1512795 A	10-07-1995
		CA 2179396 A	29-06-1995
		CN 1142828 A	12-02-1997
		CZ 9601805 A	15-01-1997
		EP 0736030 A	09-10-1996
		FI 962577 A	20-06-1996
		HU 75879 A	28-05-1997
		JP 9500658 T	21-01-1997
		NO 962616 A	07-08-1996
		NZ 278713 A	19-12-1997
		PL 315169 A	14-10-1996
		SK 82696 A	05-03-1997
		US 5714490 A	03-02-1998
		US 5703236 A	30-12-1997
		US 5693626 A	02-12-1997
		US 5710154 A	20-01-1998
		US 5703079 A	30-12-1997
		US 5661151 A	26-08-1997
		ZA 9410142 A	02-05-1996
US 5693626 A	02-12-1997	AU 5928096 A	18-12-1996
		CA 2197672 A	05-12-1996
		CZ 9700594 A	13-08-1997
		EP 0773941 A	21-05-1997
		HU 9701690 A	02-03-1998
		NO 971218 A	17-03-1997
		NZ 309281 A	28-07-1998
		PL 319635 A	18-08-1997
		SK 27097 A	10-09-1997
		WO 9638443 A	05-12-1996
		AU 681753 B	04-09-1997
		AU 1512795 A	10-07-1995
		CA 2179396 A	29-06-1995
		CN 1142828 A	12-02-1997
		CZ 9601805 A	15-01-1997
		EP 0736030 A	09-10-1996
		FI 962577 A	20-06-1996
		HU 75879 A	28-05-1997
		JP 9500658 T	21-01-1997
		NO 962616 A	07-08-1996
		NZ 278713 A	19-12-1997
		PL 315169 A	14-10-1996
		SK 82696 A	05-03-1997
		WO 9517407 A	29-06-1995
		US 5714490 A	03-02-1998
		US 5703236 A	30-12-1997
		US 5710154 A	20-01-1998
		US 5703079 A	30-12-1997
		US 5661151 A	26-08-1997
		ZA 9410142 A	02-05-1996